2022 World Conference on Lung Cancer (ePosters)-EP08.01-087. First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices

EP08.01-087. First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices

Back to course

Pdf Summary

A recent study aimed to investigate the real-world effectiveness of first-line pembrolizumab-chemotherapy for patients with advanced squamous cell carcinoma of the lung. The study used data from the Flatiron Health electronic health record (EHR)-derived database, which includes information from approximately 280 US cancer clinics.<br /><br />The study included 364 patients with advanced squamous cell carcinoma of the lung who received first-line pembrolizumab-chemotherapy. The patients had a median follow-up of 26.2 months. The study found that the real-world time on treatment (rwToT) with pembrolizumab was 6.5 months overall, and similar for patients with different levels of programmed death-ligand 1 (PD-L1) expression. The on-treatment rates were 29% at 12 months and 16% at 24 months, indicating that approximately 1 in 6 patients remained on pembrolizumab at 2 years.<br /><br />The median overall survival (OS) was 15.3 months, with 12- and 24-month OS rates of 54.9% and 37.3%, respectively. These survival outcomes were consistent regardless of PD-L1 expression. The findings of this study suggest that first-line pembrolizumab-chemotherapy provides real-world benefits for patients with advanced squamous cell carcinoma of the lung and good performance status. These results are similar to the findings from the phase 3 clinical trial KEYNOTE-407, which showed a median OS of 17.1 months with pembrolizumab-chemotherapy.<br /><br />In conclusion, first-line pembrolizumab-chemotherapy is effective in real-world settings for patients with advanced squamous cell carcinoma of the lung. The study highlights the importance of considering real-world evidence to complement clinical trial data and inform treatment decisions for this patient population.

Asset Subtitle

Stephen V. Liu

Meta Tag

Speaker Stephen V. Liu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

pembrolizumab-chemotherapy

advanced squamous cell carcinoma

lung cancer

real-world effectiveness

electronic health record

Flatiron Health

time on treatment

programmed death-ligand 1 expression

overall survival

clinical trial data